CHEK2 and breast cancer: Following a similar in silico-driven analysis strategy to that we developed to handle the case-control mutation screening data of ATM[7] and CHEK2[11], we investigated the distribution of rare coding variants in the Breast Cancer Family Registry (BCFR) population-based series composed of 1,330 early onset breast cancer cases and 1,123 controls.